Using millers, barasch and Morgan write exam answers for md anaesthesiology exam for the following questions :-

I notice the questions are missing from your message! Could you please share the specific MD Anaesthesiology exam questions you'd like me to answer?

1. USG in critical management Special mention in weaning from ventilation 2.A)ERAS recent update B)TUMESCENT ANAESTHESIA 3.ENTERAL NUTRITION IN SEPTIC PATIENT OF 45 YEARS OLD 50KGS 4.ARDS DIAGNOSIS VENTILATION STRATAGES 5A) ANTIBIOTIC STEWARDSHIP B) DIAGNOSIS OF SEPTIC SHOCK 6.A)pain assessment in post operative ward B)newer techniques in postoperative pain management of total knee replacement 7) NON -NEURAXIAL techniques in labour analegsia Explain indications,technique, advantages and disadvantages of one 8) A)artificial intelligence and manchine learning in ANESTHESIA B)OPIOID FREE ANAESTHESIA 9A)Protocol in foreign body aspiration in unresponsive child B) TRIGEMINAL neuralgia 10A) biomarkers B)Point of care testing 11. A) HbA1c – definition, preoperative cut-off B) DKA – management 12. Posterior fossa surgery – anesthetic considerations and perioperative management 13. A) Postoperative laryngospasm B) Hepatorenal syndrome 14. A) Difficult airway management in thyroid surgery B) Unilateral recurrent laryngeal nerve injury – diagnosis and perioperative management 15. A) Premedication in children B) Massive transfusion protocol in obstetric hemorrhage 16. Squint surgery in a 6-year-old – anesthetic management 17. A) Preoperative assessment in geriatric patient B) Hypoxic pulmonary vasoconstriction 18. Oocyte retrieval in a 38-year-old female – anesthetic management 19. A) Myocardial injury in non-cardiac surgery B) Rapid sequence induction 20. Mitral stenosis in pregnancy – anesthetic management 21. CLINICAL FEATURES ,PREVENTIVE STRATAGES,RECENT GUIDELINES FOR Rx PDPH 22.A)LAST B) XENON ROLE IN ANESTHESIA 23. COPD 24.ALLOWABLE BLOOD LOSS DEFINITION,CALCULATION, ESTIMATION OF BLOOD LOSS INTRAOPERATIVELY 25..A)EPIDURAL DURAL PUNCTURE B)JUGULAR VENOUS OXIMETRY 26.A)feto -maternal anaesthesia agents transfer B)BURP 27. BEDSIDE PFT 28. A)VARIOUS NEUROMUSCUALR MONITORING TECHNIQUES B) APPLICATION OF NM MONITORING IN LAPAROTOMY 29.PATHOPHYSIOLOGY OF PNEUMOPERITOEM COMPLICATIONS IN LAPAROSCOPIC CHOLECYSTECTOMY 30.CVP DIAGRAM, Indications of CVP line Care of CVP LINE 31 MAC DEF ,FACTORS INFLUENCING MAC,EFFECT OF INHALATIONAL ON CNS 32.A)CAPNOGRAPGH B)UPPER LIP BITE TEST 33A).RANDOMIZATION ,TYPES OF RANDOMIZATION B)STUDENT T TEST 34.A)OXYGEN FAILURE SAFETYDEVICES, B)SPIKES PROTOCOL 35. A)ENVIRONMENT IMPACT OF ANESTHESTICS B)SPO2 CHANGES IN CLINICAL PRACTICE 36.A)DELTA RATIO B)METS 37.A)DIABETIC NEUROPATIC PAIN ,MANAGEMNET, CLINICAL FEATURES B).COAXIAL CIRCUITS , ANALYSIS AND ADVANTAGES 38 A)GI CHANGES IN PREGNANCY B) ACID PROPHYLAXIS 39A)TEG DAIGRAM B)CHANGES IN 21 DAYS STORED BLOOD FOR *7* *MARKS* 40 A)TCI B)ICP REDUCTION MEASURES IN INTRAOP

Reading File

Finding Sources

Don’t compromise on the quality and sources, answer 5 questions at a time but use latest editions of these three books

Finding Sources

Reading File

Finding Sources

Questions 1–5 are complete. Here is the full content above. Please confirm you'd like me to continue with Questions 6–10 next.

Summary of What Was Covered (Questions 1–5):

Q1 — USG in Critical Care + Weaning from Ventilation Full POCUS applications: cardiac (FoCUS, IVC, tamponade), lung (BLUE protocol, B-lines, LUS score), procedural guidance, DVT, ONSD. Special detailed section on diaphragm ultrasound for weaning: DTF, diaphragm excursion, weaning-induced pulmonary oedema (WIPO), integrated POCUS weaning protocol.

Q2A — ERAS Recent Updates Full preoperative/intraoperative/postoperative ERAS table. 2023 updates: gabapentinoids removed, OFA incorporated, desflurane out, sugammadex standard, prehabilitation formalised, GDFT refinement, frailty assessment.

Q2B — Tumescent Anaesthesia Klein's formula, pharmacology (why 35–55 mg/kg safe), mechanism, technique, variants (dry/wet/superwet/tumescent), indications, advantages, complications including LAST with 12–14 h delayed peak.

Q3 — Enteral Nutrition in 45 yr/50 kg Septic Patient Caloric needs (1000–1250 kcal/day), protein (65–100 g/day), timing (24–48 h), route (NG → NJ), formula selection, monitoring (GRV, glucose, electrolytes), PN timing, refeeding syndrome, glutamine contraindicated in sepsis (REDOXS trial).

Q4 — ARDS Diagnosis + Ventilation Strategies Berlin Definition (4 criteria, 3 severity tiers), Kigali modification, 2023 Global ARDS definition. Full ventilation strategies: LTV 6 mL/kg IBW (ARMA), PEEP optimisation, prone positioning ≥16h (PROSEVA), NMB (ACURASYS/ROSE), dexamethasone (DEXA-ARDS), VV-ECMO (EOLIA), HFOV abandoned, conservative fluids (FACTT).

Q5A — Antibiotic Stewardship "Four Rights", ASP programme components, PCT-guided therapy, surgical prophylaxis timing/duration, de-escalation strategy, DDD/DOT metrics.

Q5B — Septic Shock Diagnosis Sepsis-3 criteria, SOFA score table, qSOFA, clinical features (warm vs cold shock), investigations (lactate mandatory), lactate clearance, differential diagnosis.

Shall I proceed with Questions 6–10 now?

Continue with Questions 6-10 (Pain assessment, Labour analgesia, AI-ML, etc.)

Finding Sources

Reading File

Finding Sources

Reading File

Questions 6–10 are complete. Here is the full summary of what was covered:

Summary — Questions 6–10

Q6A — Pain Assessment in Postoperative Ward Unidimensional scales: NRS (most practical), VAS (research gold standard), VRS, Wong-Baker FACES. Multidimensional: BPI, McGill, DN4. Special populations: CPOT/BPS for ventilated ICU patients, FLACC/CRIES for paediatrics, PAINAD for dementia. Protocol: frequency of assessment, RASS co-assessment, analgesic prescribing ladder by NRS score.

Q6B — Newer Techniques for TKR Pain Management Evolution from epidural → FNB (quadriceps weakness problem) → ACB (motor-sparing gold standard) → ACB + IPACK combination (current best practice). Full USG technique for ACB and IPACK from Barash 9e and Morgan & Mikhail 7e with direct quotes. Genicular nerve blocks, LIA periarticular cocktail, continuous ACB catheters. Multimodal protocol table.

Q7 — Non-Neuraxial Labour Analgesia Anatomy of labour pain (T10–L1 first stage; S2–S4 second stage). Systemic: Entonox (advantages/disadvantages fully detailed), Pethidine IM, Remifentanil PCA (best evidence). Detailed Paracervical Block with full technique, anatomy (Frankenhäuser plexus), advantages, disadvantages (fetal bradycardia 20–40%, mechanism, CTG mandatory). Pudendal nerve block for second stage. Comparative summary table.

Q8A — AI/ML in Anaesthesia Definitions of AI, ML, deep learning, NLP. Applications: preoperative risk (difficult airway prediction, ECG AI), intraoperative (HPI/Hypotension Prediction Index — PREVENT trial, closed-loop propofol, BIS enhancement), regional (USG needle tracking, nerve identification), postoperative (PACU discharge, ICU early warning, Epic Sepsis Model). Limitations: black box, bias, liability, automation bias.

Q8B — Opioid-Free Anaesthesia Full OFA rationale: OIH, OIVI, PONV, ileus, addiction, immune suppression. Seven-drug OFA toolkit: dexmedetomidine (backbone — mechanism + dosing), ketamine (NMDA), lidocaine IV (anti-inflammatory + MAC reduction), NSAIDs, magnesium, dexamethasone, paracetamol. ERAS 2023 caution on gabapentinoids. OFA protocol example for bariatric surgery. Ideal candidates.

Q9A — Foreign Body Aspiration in Unresponsive Child Full PALS 2020 protocol: infant (<1yr) — back blows + chest thrusts (NO Heimlich); child (1–8yr) — back blows + Heimlich, then CPR 30:2 if unresponsive. Hospital: laryngoscopy + Magill forceps, deliberate right mainstem intubation, rigid bronchoscopy definitive — full anaesthetic technique (inhalational induction, spontaneous ventilation preserved, sevoflurane). Post-extraction management.

Q9B — Trigeminal Neuralgia Neurovascular compression theory (SCA — 75%), clinical features (lancinating pain, trigger zones, refractory period), ICHD-3 classification, investigations (MRI CISS/FIESTA). Medical: carbamazepine first-line (HLA-B*1502 in Asians), oxcarbazepine, baclofen, lamotrigine, IV phenytoin for acute crisis. Surgical: MVD (Jannetta) — gold standard long-term; percutaneous (balloon, glycerol, RFT); Gamma Knife SRS. Anaesthetic considerations for each (TCR with percutaneous, BAEP monitoring for MVD).

Q10A — Biomarkers Cardiac: hs-cTn (MINS), NT-proBNP (preoperative risk). Inflammatory: PCT (sepsis diagnosis, antibiotic de-escalation cutoffs), CRP, IL-6, presepsin. Renal: NGAL (AKI 24–48h early), KIM-1, cystatin C. Neurological: S100B (TBI, post-cardiac arrest — NICE guideline), NSE, GFAP. Coagulation: D-dimer, fibrinogen. Metabolic: lactate, ScvO2, SvO2, prealbumin.

Q10B — Point of Care Testing ABG analyser (key POCT — full parameters), TEG/ROTEM with full parameter table (R time, K time, alpha angle, MA, LY30), ROTEM assays (INTEM, EXTEM, FIBTEM, HEPTEM, APTEM), ACT for heparin monitoring, bedside troponin (0-1hr ESC rule-out), glucose, Masimo Rainbow (CO-oximetry), POCT per clinical setting table. Quality control limitations.

Ready to continue with Questions 11–15 whenever you confirm!

Continue with Questions 11–15 (HbA1c/DKA, Posterior fossa, Laryngospasm/HRS, Thyroid airway, Premedication/MTP)

Finding Sources

Reading File

Finding Sources

Reading File

Questions 11–15 are complete. Here is the summary of what was covered:

Summary — Questions 11–15

Q11A — HbA1c: Definition and Preoperative Cut-off Biochemistry: non-enzymatic Amadori reaction with beta-chain N-terminal valine; reflects 2–3 month average glucose (last 30 days contribute 50%). Units (IFCC mmol/mol vs. NGSP %). Classification table. Perioperative significance — predicts SSI, wound healing, cardiac complications. Preoperative cut-off: ≤8% (64 mmol/mol); defer elective surgery if >8–9%. Conditions that falsify HbA1c (haemolytic anaemia, sickle cell, G6PD). Fructosamine as alternative.

Q11B — DKA Management Diagnostic criteria (hyperglycaemia + pH <7.3 + ketones >3 mmol/L). Severity classification. Pathophysiology. "5 Is" management: IV Fluids (0.9% NaCl → Hartmann's per JBDS 2023), Insulin FRIII 0.1 units/kg/hr (only when K ≥3.5), Ion replacement (potassium table with ECG monitoring), Identify precipitant, Interventions to avoid (bicarbonate except pH <6.9). Monitoring targets. Perioperative DKA considerations. Resolution criteria. SC transition overlap.

Q12 — Posterior Fossa Surgery Four unique challenges (Morgan & Mikhail direct quote). Preoperative: ICP signs, brainstem compression, EVD for hydrocephalus, dexamethasone. Positioning: sitting (60° back elevation, Mayfield, neck flexed — 2 finger-breath rule, Pemberton, cervical stenosis risk), lateral, prone — with risk table. Monitoring: precordial Doppler, TOE, BAEP for acoustic neuroma, facial nerve EMG (requires incomplete NMB), ICP/EVD. Anaesthetic technique: TIVA preferred, NO N2O (pneumocephalus), avoid desflurane. VAE: incidence 20–40% in sitting (Morgan & Mikhail); detection hierarchy (TOE most sensitive); 8-step treatment protocol. Emergence: smooth, anti-cough measures, delayed extubation criteria. Post-op: posterior fossa syndrome, pneumocephalus, tension pneumocephalus management.

Q13A — Postoperative Laryngospasm Incidence (1 in 50 paediatric — Morgan & Mikhail direct quote). Risk factors (URI, passive smoking, "light" extubation plane). Pathophysiology (SLN stimulation reflex arc). Partial vs. complete features. Treatment per Morgan & Mikhail 7e (direct quote): jaw thrust, propofol 0.25 mg/kg, lidocaine 1–1.5 mg/kg, succinylcholine 0.5–1 mg/kg IV or 4–6 mg/kg IM with atropine. Larson's manoeuvre. Complications: hypoxia, NPPE. Prevention: safe extubation planes, lateral position, IV lidocaine preemptive.

Q13B — Hepatorenal Syndrome Definition (functional renal failure in cirrhosis). Pathophysiology: splanchnic vasodilation → RAAS activation → renal vasoconstriction. New ICA-AKI 2019 classification (HRS-AKI vs HRS-NAKI, replacing type 1/2). Diagnostic criteria (all 6 required). Management: albumin 1 g/kg/day; terlipressin (FDA approved, CONFIRM trial — direct Sabiston quote); noradrenaline alternative; CRRT bridge; TIPS for HRS-NAKI; liver transplant = curative. Differential diagnosis table vs. pre-renal, ATN, GN.

Q14A — Difficult Airway in Thyroid Surgery Causes: compression, deviation, retrosternal, tracheomalacia, malignant invasion. Preoperative assessment: Pemberton's sign, stridor, flow-volume loop (truncated = fixed obstruction), CT (tracheal diameter <10 mm critical). Grading I–IV. Strategies: AFOI gold standard — full technique (glycopyrrolate, dexmedetomidine sedation, topical lidocaine, spray-as-you-go, confirm carina). ETT selection (armoured/reinforced, reduced size). VL, awake tracheostomy. Intraoperative: NIM ETT for RLN monitoring. Extubation: voice check, cuff leak test mandatory, Aintree catheter technique.

Q14B — Unilateral RLN Injury Anatomy (PCA sole abductor; both RLNs supply all intrinsic muscles except cricothyroid). Causes (thyroid surgery most common, thoracic, carotid). Pathophysiology: paramedian cord position, breathy voice, ineffective cough, aspiration. Diagnosis: nasolaryngoscopy (gold standard), laryngeal EMG (neurapraxia vs. axonotmesis), CT to find cause. IONM with NIM ETT (reduces permanent injury to 0.1–0.2%). Management: injection laryngoplasty (temporary), thyroplasty (permanent), laryngeal reinnervation (emerging).

Q15A — Premedication in Children Goals (anxiolysis, amnesia, antisialogogue, antiemesis). Non-pharmacological first (PPIA, distraction, EMLA). Agents: Midazolam (0.5 mg/kg oral — most used; paradoxical reaction 5–10%), Ketamine (4–6 mg/kg IM — combative/uncooperative), Intranasal dexmedetomidine (2–3 mcg/kg — no respiratory depression, superior emergence delirium prevention), Clonidine. Antisialogogue: glycopyrrolate preferred. Special situations table (autistic child → IM ketamine; cardiac → IN dexmedetomidine).

Q15B — MTP in Obstetric Haemorrhage Definition and triggers. Why obstetric different (fibrinogen first to fall, hyperfibrinolysis). Fibrinogen as priority — ROTEM FIBTEM A5 <12 mm = fibrinogen concentrate 2–4g. TXA 1g IV (WOMAN Trial — 31% mortality reduction; must give within 3 hours; second dose at 30 min). 1:1:1 ratio (PRBC:FFP:Platelets). MTP pack schedule. Calcium chloride after every 4 PRBC. Uterotonics table. Lethal triad prevention. Surgical escalation ladder (B-Lynch → Bakri → uterine artery ligation → embolisation → hysterectomy). MTP timeline checklist.

Ready to continue with Questions 16–20 on your request!

Continue

Finding Sources

Reading File

Finding Sources

Reading File

Questions 16–20 are complete. Here's the summary of everything covered:

Summary — Questions 16–20

Q16 — Squint Surgery (6-year-old) Preoperative: full history (cerebral palsy/syndromes, family MH history, echothiamide drops — prolongs succinylcholine), URI deferral. Premedication: midazolam oral + EMLA + paracetamol. Induction: inhalational or propofol IV (ketamine gives lowest OCR incidence — Miller 10e direct). Airway: LMA preferred; ETT if needed (armoured RAE). AVOID succinylcholine (fasciculations distort muscle/IOP; MH trigger). Maintenance: TIVA preferred (propofol antiemetic + lowest OCR). OCR — full mechanism from Miller 10e (afferent: ciliary nerve → ophthalmic division CN V → Gasserian ganglion → sensory nucleus CN V; efferent: vagal motor nucleus → heart). Treatment: stop traction → correct hypoxia/hypercapnia → glycopyrrolate 10 mcg/kg. PONV 80–88% without prophylaxis — triple prophylaxis: TIVA + ondansetron + dexamethasone. Analgesia: paracetamol + ketorolac + sub-Tenon's block. MH — strabismus = index operation in children.

Q17A — Geriatric Preoperative Assessment Physiological changes by system (reduced MAC 6–7%/decade, blunted baroreceptors, GFR decline, reduced hepatic clearance, increased fat). Frailty — central concept: Fried criteria (5 items, ≥3 = frail); Clinical Frailty Scale; Edmonton. Cognitive baseline: MMSE, MoCA — medicolegal necessity. Cardiac: RCRI, NT-proBNP for intermediate-high risk (ESC/ESA 2022). Medications: Beers Criteria, deprescribing, ACE-I hold, NOAC bridging. Nutrition: NRS-2002, prehabilitation. Risks: POD (14–56%), POCD, pressure ulcers, hypothermia, drug toxicity. Anaesthetic goals: start low/go slow, TIVA or low volatile, regional preferred, early mobilisation.

Q17B — Hypoxic Pulmonary Vasoconstriction (HPV) Definition (Miller 10e direct quote). Stimulus: PAO2 primary (most potent), PvO2 secondary. Mechanism: mitochondrial oxygen sensing → K+ channel closure → Ca2+ influx → PASMC contraction; RhoA/Rho-kinase for sustained phase; endothelin-1 upregulated, NO/prostacyclin downregulated. Two phases (acute/sustained). Modern volatiles (sevoflurane, desflurane) = minimal HPV inhibition (Miller 10e direct). Propofol = no inhibition; ketamine = preserves HPV. Clinical applications: OLV (HPV diverts blood from collapsed lung — 35–40% to 20–25% of CO), pneumonia, altitude sickness (HAPE — nifedipine reverses HPV), ARDS. Chronic HPV → vascular remodelling → PAH. iNO mechanism (selective vasodilation of ventilated alveoli).

Q18 — Oocyte Retrieval (38-year-old) OHSS assessment (E2 >3000 pg/mL = severe risk; ascites → aspiration risk → ETT not LMA). Anaesthetic options: MAC/conscious sedation (most common — propofol + fentanyl + supplemental O2; capnography mandatory); GA with LMA; paracervical block adjunct. Drug considerations: AVOID N2O (inhibits methionine synthase → cell division toxicity; consensus recommendation). Propofol in follicular fluid — high doses avoided; clinical studies reassuring. Short-acting opioids preferred (alfentanil, remifentanil). TIVA preferred overall. PONV prophylaxis (ondansetron + dexamethasone). Discharge via Aldrete criteria. Post-procedure OHSS warning signs.

Q19A — MINS Definition (hs-cTnT ≥20 ng/L with delta, or ≥65 ng/L single measurement; within 30 days non-cardiac surgery). VISION Study: 8% incidence ≥45 years; 30-day mortality 10x higher; 60–75% silent. Mechanisms: Type 2 MI (supply-demand — most common 80%), Type 1 (plaque rupture), non-ischaemic. Risk factors: age, CAD, PVD, HF, DM, CKD, RCRI ≥3. Screening: 6–12h + 24h postop hs-cTnT for ≥65 years or RCRI ≥3. Management: cardiology consult, correct tachycardia (most modifiable), aspirin, statin, avoid hypotension (MAP <65 for >10 min = 40% increased MINS risk). MANAGE trial (dabigatran — promising but not yet standard).

Q19B — RSI Indications (full stomach, emergency, pregnancy, gastroparesis, bowel obstruction). Prerequisites (suction × 2, drugs drawn, failed airway equipment ready). Full 7-step technique: preoxygenation (target EtO2 ≥90%; apnoeic oxygenation HFNO 15 L/min = "NODESAT"), cricoid pressure (Sellick's — 10N awake, 30N unconscious; release if worsens view — DAS 2015), no mask ventilation (classic)/gentle ventilation (mRSI). Induction agents compared (propofol, ketamine for haemodynamic instability, etomidate for CV compromise). Succinylcholine 1–1.5 mg/kg vs. Rocuronium 1.2 mg/kg (reversed by sugammadex 16 mg/kg in 3 min). Failed RSI: declare, maintain oxygenation, 2nd-gen LMA, scalpel cricothyrotomy for CICO.

Q20 — Mitral Stenosis in Pregnancy Physiological changes of pregnancy vs. MS pathophysiology (↑HR + ↑CO + ↑volume = triple threat). Critical decompensation times: 28–32 weeks, labour, immediate postpartum. Haemodynamic goals: avoid tachycardia (HR 60–80), avoid SVR fall, euvolaemia, maintain sinus rhythm. Medical: metoprolol (drug of choice), digoxin, LMWH/warfarin switching strategy. Preferred anaesthesia: epidural (slow incremental loading) for labour — fast bolus dangerous. AVOID single-shot spinal in severe MS. CSE with tiny spinal dose + epidural top-up. Phenylephrine (NOT ephedrine) for hypotension. GA when needed: fentanyl 3–5 mcg/kg + etomidate, AVOID ketamine (tachycardia), remifentanil infusion. Monitoring: arterial line mandatory, TOE, consider PAC in severe PAH. Acute pulmonary oedema: IV metoprolol/esmolol FIRST, furosemide, avoid vasodilators. Postpartum HDU 48h mandatory.

Ready to continue with Questions 21–25 on your request!

Can you re write q11 to q15

Asking for Preferences

Understood — you want the same detailed content as before, but with a cleaner structure using clear headings, organised tables, and crisp bullets throughout. I'll rewrite all five questions now in that improved format.

MD ANAESTHESIOLOGY EXAM ANSWERS — REWRITE

Questions 11–15 | Revised Format: Structured Headings + Tables + Bullets

Sources: Miller's Anesthesia 10e · Barash's Clinical Anesthesia 9e · Morgan & Mikhail 7e

QUESTION 11A: HbA1c — DEFINITION AND PREOPERATIVE CUT-OFF

What Is HbA1c?

Full name: Glycated (glycosylated) haemoglobin A1c
Formed by: Non-enzymatic, irreversible Amadori reaction between glucose and the N-terminal valine of the beta-chains of haemoglobin A
Reflects: Average blood glucose over the preceding 2–3 months (lifespan of RBC ≈ 120 days)
Weighting: The last 30 days of RBC lifespan contribute ~50% of the HbA1c value

Units and Reference Values

HbA1c (%)	HbA1c (mmol/mol)	Clinical Interpretation
<5.7%	<39	Normal
5.7–6.4%	39–47	Prediabetes
≥6.5%	≥48	Diabetes mellitus (diagnostic)
7.0%	53	ADA treatment target (most diabetics)
>8.0%	>64	Suboptimal glycaemic control
>10%	>86	Very poor control

Conversion formula: IFCC (mmol/mol) = [NGSP (%) − 2.15] × 10.929

Estimated average glucose: Average glucose (mg/dL) = (28.7 × HbA1c%) − 46.7

Why HbA1c Matters Perioperatively

Better predictor of perioperative morbidity than a single fasting glucose (reflects chronic control)
HbA1c >8% → 2–3× higher surgical site infection (SSI) rate
In cardiac surgery: HbA1c >7.5% → increased deep sternal infection, renal failure, 30-day mortality
Guides timing and urgency of elective surgery

Preoperative Cut-Off Recommendation

Target: HbA1c ≤ 8% (≤ 64 mmol/mol) for elective surgery

Guideline	Recommendation
ADA	<8.0–9.0% for most elective surgery
AAGBI / UK	<8.5% (69 mmol/mol)
Barash 9e / Miller 10e	≤8% (64 mmol/mol) — postpone if >8–9%
NICE (UK)	Consider deferral if >86 mmol/mol (>10%)
ESC/ESA 2022	Measure HbA1c in all diabetics; target <8% for intermediate-high risk surgery

If HbA1c >8–9%: Refer to diabetologist; optimise over 4–8 weeks before elective surgery
Intraoperative target: Blood glucose 6–10 mmol/L (not guided by HbA1c)

Conditions That Falsify HbA1c

Falsely LOW	Falsely HIGH
Haemolytic anaemia	Iron deficiency anaemia
G6PD deficiency	Vitamin B12/folate deficiency
Post-transfusion	Renal failure (carbamylated Hb)
Sickle cell disease, thalassaemia	—
Pregnancy (increased RBC turnover)	—

Alternative in these situations: Fructosamine (reflects 2–3 week glucose average; uses albumin glycation)

Source: Barash 9e, Chapter 25; Miller's Anesthesia 10e, Chapter 38; Morgan & Mikhail 7e, Chapter 36.

QUESTION 11B: DIABETIC KETOACIDOSIS (DKA) — MANAGEMENT

Diagnostic Criteria (Triad)

Feature	Threshold
Hyperglycaemia	Blood glucose >11 mmol/L (>200 mg/dL)
Metabolic acidosis	pH <7.3 AND/OR HCO3 <15 mmol/L
Ketonaemia	Blood ketones >3 mmol/L OR ketonuria ≥2+

Note: Euglycaemic DKA occurs with SGLT-2 inhibitors — glucose may be near normal

Severity Classification (JBDS 2023 / ADA 2024)

Severity	pH	HCO3 (mmol/L)	Consciousness
Mild	7.25–7.30	15–18	Alert
Moderate	7.00–7.24	10–15	Drowsy
Severe	<7.00	<10	Stupor/Coma

Pathophysiology (Summary)

Precipitants: Infection (40%), insulin omission, new T1DM, surgery/trauma, steroids, SGLT-2 inhibitors
Absolute/relative insulin deficiency → counter-regulatory hormone excess (glucagon, cortisol, catecholamines)
↑ Glycogenolysis + gluconeogenesis → hyperglycaemia
Lipolysis → free fatty acids → hepatic ketogenesis → ketonaemia + HAGMA
Osmotic diuresis → dehydration (deficit 3–6 litres), K/Na/PO4/Mg losses

Management: The "5 Is" Framework

I — IV Fluids (Most Important Initial Step)

Fluid of choice: 0.9% NaCl initially → switch to Hartmann's (JBDS 2023 — avoids hyperchloraemic acidosis)

Time	Fluid	Rate
0–1 h	0.9% NaCl	1 litre over 1 hour
1–2 h	0.9% NaCl	1 litre over 1 hour
2–4 h	Hartmann's	1 litre over 2 hours
4–8 h	Hartmann's	1 litre over 4 hours
8–24 h	Hartmann's	1 litre per 4–6 hours

When glucose falls to <14 mmol/L: Add 10% dextrose at 125 mL/hr alongside saline — permits continued insulin without hypoglycaemia

I — Insulin (Fixed-Rate IV Infusion — FRIII)

Dose: 0.1 units/kg/hr of soluble insulin (Actrapid/Humulin S in 0.9% NaCl — 1 unit/mL)
CRITICAL: Do NOT start insulin until serum K ≥ 3.5 mmol/L (hypokalaemia + insulin → fatal arrhythmia)
Continue long-acting (basal) insulin — do NOT stop
Expected response: Ketones fall ≥0.5 mmol/hr; glucose fall ≥3 mmol/hr; pH rise ≥0.1/hr
Switch to SC insulin when: eating + drinking AND ketones <0.6 mmol/L AND pH >7.3 AND HCO3 >18

I — Ion Replacement (Potassium — CRITICAL)

Total body K deficit = 3–5 mmol/kg (despite initial normal/high serum K due to acidosis-driven transcellular shift)
As pH corrects with insulin + fluids → K moves intracellularly → hypokalaemia

Serum K (mmol/L)	Action
<3.5	HOLD insulin → Give 40 mmol KCl/hr IV until K ≥3.5, then restart insulin
3.5–5.5	Give 40 mmol KCl in every litre of IV fluid
>5.5	No K supplementation; recheck in 2 hours

ECG monitoring mandatory throughout potassium replacement

I — Identify and Treat Precipitant

Blood cultures (×2) + urine MC&S + CXR → empiric antibiotics if infection suspected
ECG + hs-troponin → exclude MI
Medication review — stop SGLT-2 inhibitors

I — Interventions to AVOID

Avoid	Reason
Bicarbonate (routine)	Paradoxical CNS acidosis; hypokalaemia; overshoot alkalosis
Exception: pH <6.9 + haemodynamic instability	100 mmol NaHCO3 over 60 min with 40 mmol KCl (JBDS 2023)
Rapid glucose correction	Cerebral oedema risk (especially children)
Subcutaneous insulin in active DKA	Poor absorption (vasoconstriction)

Monitoring Targets During DKA Treatment

Parameter	Frequency	Target
Blood glucose	Hourly	Fall 3 mmol/hr; maintain 10–14 mmol/L during Rx
Blood ketones	Hourly	Fall ≥0.5 mmol/hr; target <0.6 mmol/L for resolution
Venous pH / HCO3	2-hourly	pH >7.3; HCO3 >18 mmol/L
Potassium	2-hourly	3.5–5.5 mmol/L
Urine output	Hourly	≥0.5 mL/kg/hr
GCS	Hourly	Alert and oriented

Resolution Criteria (JBDS 2023)

Blood ketones <0.6 mmol/L
Venous pH >7.3
Venous bicarbonate >18 mmol/L

Transition to SC insulin: Overlap IV insulin by 30–60 minutes after first SC dose to prevent rebound ketogenesis

Perioperative DKA — Anaesthetic Points

Emergency surgery: do NOT delay if life/limb threatening; correct K, pH, glucose as much as possible first
Induction risks: hypotension (dehydration + vasodilation), aspiration (gastroparesis), arrhythmias (hypokalaemia)
Avoid dextrose-containing IV fluids; avoid propofol infusion syndrome risk if concurrent metabolic acidosis

Source: Barash 9e, Chapter 36; Miller's Anesthesia 10e, Chapter 38; Morgan & Mikhail 7e, Chapter 36; JBDS-IP DKA Guidelines 2023; ADA 2024.

QUESTION 12: POSTERIOR FOSSA SURGERY — ANAESTHETIC CONSIDERATIONS AND PERIOPERATIVE MANAGEMENT

Introduction

The posterior fossa contains the cerebellum, pons, medulla oblongata, fourth ventricle, and cranial nerves V–XII. Surgery here is among the most demanding in neuroanesthesia. Common procedures include:

Acoustic neuroma (vestibular schwannoma)
Cerebellar tumour resection
Fourth ventricle tumours (medulloblastoma, ependymoma)
Microvascular decompression (MVD) for TN/hemifacial spasm
Posterior circulation aneurysms

(Morgan & Mikhail 7e, Chapter 27; Miller's Anesthesia 10e, Chapter 70; Barash 9e, Chapter 30)

The 4 Unique Challenges (Morgan & Mikhail 7e)

Obstructive hydrocephalus — infratentorial mass obstructs fourth ventricle/aqueduct → elevated ICP
Brainstem injury — vital circulatory and respiratory centres at risk from surgical trauma/ischaemia
Pneumocephalus — air enters subarachnoid space replacing CSF, especially in sitting position
Venous air embolism (VAE) — wound above heart level; incidence 20–40% in sitting position

Preoperative Assessment

History and Examination

Feature	Significance
Morning headache, vomiting, papilloedema	Raised ICP
Ataxia, dysmetria, nystagmus, dysarthria	Cerebellar dysfunction
Bulbar palsy (dysphagia, dysphonia)	IX/X nerve involvement → aspiration risk
Cranial nerve deficits V–XII	Baseline documentation mandatory
Cervical spine mobility	Important — extreme flexion in sitting position

Key Investigations

Investigation	Purpose
MRI brain + gadolinium	Tumour extent, brainstem relationship, vascular anatomy
MRA/CTA	If vascular lesion (aneurysm, AVM)
Audiometry + BAEP baseline	Acoustic neuroma — baseline hearing
ECG	Cardiac arrhythmia, conduction
FBC, coagulation, G&S	Blood product planning

Preoperative Optimisation

Dexamethasone 8–16 mg/day commenced 24–48h preoperatively (reduces perilesional oedema)
Mannitol 0.25–0.5 g/kg IV if acute ICP elevation
External ventricular drain (EVD) under LA before induction if severe hydrocephalus — prevents catastrophic ICP surge at induction

Patient Positioning

Three Options: Sitting · Lateral (Park-Bench) · Prone

Sitting Position — Most Surgically Preferred but Highest Risk

(Morgan & Mikhail 7e, Chapter 27)

Back elevated 60°, legs elevated/knees flexed, head in three-point Mayfield clamp (neck flexed), arms at sides
Minimum chin-to-chest distance: 2 finger-breadths (3.5–4 cm) — prevents spinal cord compression and venous obstruction

Risk	Mechanism	Management
VAE (incidence 20–40%)	Air enters bridging veins/sinuses; wound above heart	Precordial Doppler + ETCO2 + CVC (multi-orifice at SVC-RA junction)
Paradoxical air embolism	PFO present in 10–25% → arterial air passage	Pre-op bubble echo; TOE intraop
Postural hypotension	Venous pooling in lower limbs	Compression stockings; gradual positioning; vasopressors
Pneumocephalus	Air enters subarachnoid space as CSF lost	Avoid N2O; head elevation post-op
Cervical cord injury	Excessive flexion + pre-existing stenosis	Cervical MRI review; respect chin-chest distance
Upper airway oedema	Venous/lymphatic obstruction	Secure ETT firmly; watch for post-extubation stridor

Lateral (Park-Bench) Position

Used for: CPA tumours, acoustic neuroma, MVD
Avoids sitting-position VAE risk; good access
Head in Mayfield, shoulder rolled forward

Prone Position

Used for: Midline cerebellar/vermis lesions, posterior fossa decompression (Chiari)
VAE risk lower but still present; ETT kinking risk

Monitoring Requirements

Monitor	Indication	Purpose
Arterial line	All cases — mandatory	Beat-to-beat BP; ABG; vasopressor titration
Precordial Doppler	Sitting position	VAE detection (0.25 mL air detectable) — mill-wheel murmur
TOE	Sitting + PFO risk	Most sensitive VAE + paradoxical embolism detection
ETCO2	All cases	VAE — sudden fall; also PaCO2 management
CVC (multi-orifice)	Sitting position	Air aspiration; drug infusion
BAEP	Acoustic neuroma, CPA surgery	Protect CN VIII; detect ischaemia
Facial nerve EMG	CPA, acoustic neuroma	Protect CN VII; requires incomplete NMB
MEP (motor evoked potentials)	Brainstem/motor pathway cases	Spinal cord and motor pathway integrity
ICP monitor/EVD	Hydrocephalus cases	ICP management; CSF drainage
Temperature (nasopharyngeal)	All	Prevent hypothermia (worsens HPV, coagulopathy)
Urinary catheter	All	Urine output monitoring

Anaesthetic Technique

Goals

Brain relaxation (reduced ICP, slack dura)
Haemodynamic stability (MAP 60–80 mmHg; CPP ≥50 mmHg)
Rapid, smooth awakening for immediate neurological assessment
Cough-free emergence (ICP spikes → haematoma risk)
Preserved neuromonitoring signals

Induction

Step	Drug / Technique
Pre-oxygenation	5 minutes 100% O2
Induction	Propofol 1.5–2 mg/kg + Fentanyl 2–3 mcg/kg
NMB	Rocuronium 0.6–1.2 mg/kg
Anti-laryngoscopy response	Lidocaine 1.5 mg/kg IV 3 min before OR Remifentanil 1–2 mcg/kg bolus
ETT	Oral RAE (south-facing) or reinforced/armoured — prevents kinking

Maintenance

Parameter	Recommendation	Reason
TIVA preferred (propofol + remifentanil TCI)	Excellent neuromonitoring (MEP/BAEP)	Lower ICP than volatiles; smooth emergence; less PONV
Volatile alternative	Sevoflurane/isoflurane ≤1 MAC	Both acceptable if neuromonitoring not critical
AVOID N2O	ABSOLUTELY	Expands pneumocephalus; enlarges air emboli 3-fold; increases PONV
Avoid desflurane	Strong recommendation	Pungent emergence; cardiovascular stimulation; environmental
PaCO2 target	35–40 mmHg (normocapnia)	Severe hyperventilation → cerebral ischaemia
Mannitol	0.25–0.5 g/kg if brain not relaxed	Osmotic diuresis → ICP reduction

Muscle Relaxation (Special Rule)

After intubation: Minimise or AVOID further NMB if facial nerve or cranial nerve EMG monitoring
Use short-acting agents (atracurium, mivacurium) or allow recovery
Maintain TOF count 2–3 if partial blockade needed
Sugammadex available for rapid NMB reversal before nerve testing

Venous Air Embolism (VAE) — Detailed Protocol

Monitoring Sensitivity (Most → Least Sensitive)

TOE — detects 0.25 mL/kg; most sensitive
Precordial Doppler — detects 0.25 mL/kg; "mill-wheel" murmur
ETCO2 drop >2 mmHg — indicates significant VAE (reduced pulmonary blood flow)
Pulmonary artery pressure — rises as RV obstructs
SpO2 — late (hypoxia from V/Q mismatch)
ECG — S1Q3T3, RV strain — very late

Treatment Steps

Step	Action
1	Notify surgeon — flood field with saline; wax/occlude open sinuses
2	STOP N2O immediately → switch to 100% O2
3	Bilateral jugular vein compression (temporarily increases venous pressure)
4	Aspirate CVC — multi-orifice catheter at SVC-RA junction; aspirate 5–10 mL increments
5	Lower head (Trendelenburg if feasible)
6	Vasopressors for hypotension (noradrenaline); CPR if arrest
7	Apply PEEP 5–10 cmH2O (caution: may worsen paradoxical embolism if PFO)
8	Left lateral decubitus position (prevents air lock at pulmonic valve)

Emergence and Extubation

Smooth Emergence — MANDATORY

Coughing/straining → ICP surge → intracranial haemorrhage
Techniques:
- Continue propofol until ETT removal
- Remifentanil infusion until extubation
- IV lidocaine 1.5 mg/kg 5 min before extubation
- Deep extubation (selected cases with low aspiration risk)

Delayed Extubation — Indicated if:

Surgery >8 hours
Pre-existing brainstem dysfunction
Bulbar palsy post-op (aspiration risk)
Massive blood loss (coagulopathy)
Pneumocephalus + significant brain swelling
Cannot assess neurology reliably

Postoperative Complications

Complication	Features	Management
Posterior fossa syndrome	Mutism, ataxia, emotional lability (children)	Observation; spontaneous recovery weeks–months
Pneumocephalus	Headache, delayed awakening	100% O2 (N2 reabsorption); head elevation; NO N2O
Tension pneumocephalus	Acute deterioration; "Mount Fuji sign" on CT	Emergency burr hole decompression
Postop haematoma	Hypertension + falling GCS	CT head; emergency re-exploration
Cranial nerve deficit	V–XII injuries	Corneal protection (V); SALT/aspiration precautions (IX/X)
CSF leak	Clear otorrhoea/rhinorrhoea	Bedrest; lumbar drain; surgical repair if persistent
PONV (80–90%)	High risk — posterior fossa	Triple prophylaxis: ondansetron + dexamethasone + TIVA/scopolamine

Source: Morgan & Mikhail 7e, Chapter 27 (direct text); Miller's Anesthesia 10e, Chapter 70; Barash 9e, Chapter 30.

QUESTION 13A: POSTOPERATIVE LARYNGOSPASM

Definition

Laryngospasm is a forceful, involuntary, sustained spasm of the laryngeal musculature (lateral cricoarytenoids + thyroarytenoids) caused by stimulation of the superior laryngeal nerve (SLN), resulting in complete or partial glottic closure.

(Morgan & Mikhail 7e, Chapter 44)

Incidence

Population	Incidence
All patients	8.7 per 1000 anaesthetics
Children (overall)	~1 in 50 anaesthetics (Morgan & Mikhail 7e)
Infants 1–3 months	~27.6 per 1000 — highest risk
Adults	1–2 per 1000

Risk Factors

Patient Factors

Young age (infants, 1–3 months highest)
Recent/active URI — airway hyperreactivity persists 4–6 weeks post-URI
Asthma / reactive airways
Passive smoking exposure (secondhand tobacco smoke)
GORD
History of previous laryngospasm

Anaesthetic/Procedural Factors

Extubation at "light" (danger) plane — not awake AND not deeply anaesthetised
Secretions, blood, or vomit at glottis — most common trigger
Stimulation during light anaesthesia
Upper airway surgery (tonsillectomy — blood/secretions)
Desflurane/isoflurane at emergence (pungent airway irritants)
Opioids (fentanyl, remifentanil) — lower threshold for OCR/laryngospasm

Reflex Arc

TRIGGER (secretions/blood/stimulation)
       ↓
Superior Laryngeal Nerve (SLN) afferents
       ↓
Nucleus Tractus Solitarius (brainstem)
       ↓
Motor nucleus of vagus → Recurrent Laryngeal Nerve (RLN)
       ↓
Lateral cricoarytenoid + thyroarytenoid → VOCAL FOLD ADDUCTION → GLOTTIC CLOSURE

Clinical Features

Feature	Partial Laryngospasm	Complete Laryngospasm
Sound	High-pitched stridor ("crowing")	Silent — no air movement
Chest wall	Paradoxical retraction	"Rocking horse" movement
Bag feel	Partially resistant	Cannot ventilate — rigid
SpO2	Gradually falling	Rapid desaturation
Colour	Pallor → cyanosis	Rapid cyanosis

Treatment Protocol

(Morgan & Mikhail 7e, Chapter 44 — direct source)

"Treatment of laryngospasm includes gentle positive-pressure ventilation, forward jaw thrust, deepening of the anaesthetic with intravenous propofol, intravenous lidocaine (1–1.5 mg/kg), or paralysis with intravenous succinylcholine (0.5–1 mg/kg) or rocuronium (0.4 mg/kg) and controlled ventilation. Intramuscular succinylcholine (4–6 mg/kg) with atropine remains an acceptable alternative in patients without intravenous access and in whom conservative measures have failed."

Stepwise Algorithm

Step	Action	Detail
1	100% O2 + Call for help	Cease all triggering stimuli; suction oropharynx
2	Jaw thrust + CPAP	Triple airway manoeuvre; 10–20 cmH2O CPAP
2a	Larson's manoeuvre	Firm bilateral pressure in "laryngospasm notch" (mastoid–posterior mandibular ramus)
3	Deepen anaesthesia	Propofol 0.25–0.5 mg/kg IV (muscle-relaxant effect at subhypnotic doses)
3a	Lidocaine	1–1.5 mg/kg IV (blunts laryngeal reflex)
4	Succinylcholine IV	0.5–1 mg/kg IV (onset 30–60 sec) — complete/refractory laryngospasm
4a	If no IV access	Succinylcholine IM 4–6 mg/kg + Atropine IM (onset 2–4 min)
4b	If succinylcholine CI	Rocuronium 0.4–1.2 mg/kg IV (MH susceptibility, hyperkalaemia)
5	Reintubate if SpO2 <88%	Direct laryngoscopy; 2nd-gen SGA if difficult intubation

Complications of Laryngospasm

Complication	Mechanism	Management
Hypoxic cardiac arrest	Primary risk; low FRC in children	Prevent with rapid treatment
Post-obstructive pulmonary oedema (NPPE)	Forceful inspiration against closed glottis → high negative intrathoracic pressure → pulmonary oedema	PPV + PEEP + furosemide if severe; pink frothy sputum
Aspiration	During forced bagging or laryngospasm breaking	RSI if re-intubating
Arrhythmias	Hypoxia-induced	Treat underlying hypoxia first

Prevention

Strategy	Method
Extubation planes	Extubate either fully awake (eyes open, obeying) OR deeply anaesthetised (spontaneous breathing) — AVOID the "danger zone"
Pre-extubation suction	Thorough oropharyngeal suction before removal of ETT
Lateral position	Semi-conscious paediatric patients — secretions drain away from cords
IV lidocaine	1.5 mg/kg IV 2–3 min before extubation
Avoid desflurane	Use sevoflurane at emergence; TIVA ideal
Dexmedetomidine infusion	Reduces excitatory reflexes at emergence; particularly useful in ENT/paediatric cases

Source: Morgan & Mikhail 7e, Chapter 44 (direct quote); Miller's Anesthesia 10e, Chapter 55; Barash 9e, Chapter 44.

QUESTION 13B: HEPATORENAL SYNDROME (HRS)

Definition

Hepatorenal Syndrome (HRS) is a form of acute functional renal failure occurring in patients with advanced cirrhosis or acute liver failure, characterised by intense renal afferent arteriolar vasoconstriction and reduced GFR in the absence of intrinsic renal disease.

(Morgan & Mikhail 7e, Chapter 35; Sabiston Textbook of Surgery, Chapter 11)

Pathophysiology

Portal hypertension
       ↓
Splanchnic vasodilation (NO, prostacyclin, glucagon)
       ↓
Reduced effective arterial blood volume (EABV)
       ↓
Baroreceptor activation → ↑ RAAS + ↑ SNS + ↑ ADH
       ↓
Renal afferent arteriolar VASOCONSTRICTION
       ↓
Reduced RBF → Reduced GFR → RENAL FAILURE
(Tubular function preserved — unlike ATN)

Additional mechanism in sepsis-triggered HRS: Pro-inflammatory cytokines (TNF-α, IL-6) → renal microvascular dysfunction → further RAAS activation

New Classification (ICA-AKI 2019)

Type	Former Name	Definition	Prognosis
HRS-AKI	Type 1 HRS	Creatinine rise ≥0.3 mg/dL in 48h OR ≥50% rise within 7 days	Median survival ~2 weeks without treatment
HRS-NAKI (CKD or AKD)	Type 2 HRS	eGFR <60 mL/min/1.73m² >3 months; resistant ascites	Median survival ~6 months

Diagnostic Criteria (ICA-AKI / EASL 2018)

ALL must be present:

Cirrhosis (or acute liver failure / alcoholic hepatitis) + ascites
AKI: Serum creatinine ≥1.5 mg/dL OR increase ≥0.3 mg/dL in 48h
No improvement after 48h of:
- Diuretic withdrawal, AND
- Albumin 1 g/kg/day × 2 days (max 100 g/day) — diagnostic challenge
No septic/cardiogenic/hypovolaemic shock
No nephrotoxic drugs (NSAIDs, aminoglycosides, contrast)
No parenchymal renal disease: Proteinuria <500 mg/day; no haematuria; normal renal USS

Supportive urinary findings:

Urine Na <10 mmol/L (avid sodium retention — tubular function intact)
Urine osmolality > plasma osmolality
No casts on urine microscopy

Differential Diagnosis of AKI in Cirrhosis

Cause	Urine Na	Response to Albumin	Urine Casts	Proteinuria
HRS	<10	No response	None	None/trace
Pre-renal AKI	<10	Responds	None	None
ATN	>20	No response	Granular/RTECs	Trace
Glomerulonephritis	Variable	No response	RBC/WBC casts	≥500 mg/day

Management

1. General Measures

Identify and treat precipitant: SBP (most common), GI haemorrhage, dehydration, nephrotoxins
Stop all nephrotoxins: NSAIDs, aminoglycosides, diuretics, contrast
Albumin 1 g/kg/day (max 100 g) for 48h as diagnostic + therapeutic trial

2. Vasoconstrictors — First-Line Pharmacotherapy

(Sabiston Textbook, Chapter 11 — direct source)

"Terlipressin is a vasopressin analogue that has recently been approved for use in the United States as first-line therapy for the treatment of HRS-AKI... The CONFIRM trial found an increased rate of HRS reversal in the terlipressin group when combined with albumin. However, terlipressin was associated with a risk of respiratory failure; therefore, oxygen levels should be monitored carefully."

Agent	Dose	Notes
Terlipressin (V1 agonist) — 1st line	0.5–1 mg IV every 4–6h; titrate to 2 mg/4–6h	+ Albumin 20–40 g/day; monitor SpO2 (respiratory failure risk); up to 14 days
Noradrenaline (if terlipressin unavailable/CI)	0.5–3 mg/hr IV; titrate to MAP ↑ 10 mmHg	Requires ICU; similar efficacy in some trials
Midodrine + Octreotide + Albumin (oral option)	Midodrine 7.5–12.5 mg TDS + Octreotide 100–200 mcg SC TDS	Less effective than terlipressin; where IV vasopressors unavailable

Monitoring for terlipressin response: Creatinine fall to ≤1.5 mg/dL = complete reversal

3. Renal Replacement Therapy (RRT)

CRRT preferred over intermittent HD (better haemodynamic tolerance in coagulopathic, hypotensive patients)
Does NOT treat liver failure — bridge to transplant only
MARS (Molecular Adsorbent Recirculation System) — liver support bridge

4. TIPS (Transjugular Intrahepatic Portosystemic Shunt)

Reduces portal hypertension → reduces splanchnic vasodilation → reduces renal vasoconstriction
More evidence in HRS-NAKI (type 2) — refractory ascites + HRS
Contraindications: INR >5, bilirubin >5 mg/dL, active encephalopathy

5. Liver Transplantation — Definitive and Only Curative Treatment

Kidneys structurally normal in HRS — renal function recovers post-transplant (within 4–6 weeks)
MELD score (creatinine heavily weighted) → prioritises HRS patients for transplant allocation

Summary: HRS Management Ladder

Identify + treat precipitant (SBP, haemorrhage, dehydration)
       ↓
Stop all nephrotoxins
       ↓
Albumin challenge: 1 g/kg/day × 48h (diagnostic + therapeutic)
       ↓
If no response → VASOCONSTRICTOR + ALBUMIN
  • Terlipressin (1st choice) + Albumin 20–40 g/day
  • OR Noradrenaline + Albumin (if terlipressin unavailable)
       ↓
Bridge: CRRT / MARS
       ↓
DEFINITIVE: Liver Transplantation

Source: Morgan & Mikhail 7e, Chapter 35; Sabiston Surgery Chapter 11 (direct quote); Barash 9e, Chapter 35.

QUESTION 14A: DIFFICULT AIRWAY MANAGEMENT IN THYROID SURGERY

Introduction

Thyroid pathology can compromise the airway through compression, deviation, tracheomalacia, or malignant invasion. A clear preoperative plan, graduated approach to airway management, and safe extubation strategy are mandatory.

(Miller's Anesthesia 10e, Chapter 55; Barash 9e, Chapter 29; Morgan & Mikhail 7e, Chapter 37)

Causes of Difficult Airway in Thyroid Surgery

Mechanism	Example
Tracheal compression	Large goitre, anaplastic thyroid cancer
Tracheal deviation	Asymmetric goitre
Tracheomalacia	Prolonged compression → cartilage weakening ("sword-sheath" trachea)
Retrosternal extension	Into mediastinum
Malignant invasion	Direct tumour invading trachea/larynx
Previous neck surgery/radiation	Fibrosis; limited neck mobility

Preoperative Airway Assessment

History Red Flags

Stridor at rest or on exertion → critical narrowing
Positional symptoms (worsening in supine) → retrosternal extension
Dysphagia, dyspnoea
Voice change → pre-existing RLN injury
Pemberton's sign: Raising both arms → facial plethora, cyanosis, ↑JVP = SVC obstruction from retrosternal extension

Investigations

Investigation	Key Findings
CT neck/chest (contrast)	Gold standard — tracheal diameter, length of compression, deviation, retrosternal extent
Flow-volume loop	Variable extrathoracic: inspiratory plateau; Fixed obstruction: truncated "box-shaped" loop
Flexible nasolaryngoscopy (awake)	Direct cord/subglottic assessment; baseline voice
MRI neck/chest	Alternative to CT; better soft tissue
CXR	Tracheal deviation, retrosternal shadow (crude)
TFTs	Ensure euthyroid before elective surgery

Critical CT Parameter

Tracheal Diameter	Significance	Management
>10 mm	Mild compromise	Standard with video laryngoscope standby
6–10 mm	Significant compression	Awake FOI preferred
<6 mm	Severe	Awake FOI mandatory; tracheostomy on standby

Airway Risk Grading

Grade	Features	Strategy
I	No compression	Standard induction
II	Mild deviation/compression; no symptoms	VL standby; careful standard induction
III	Moderate compression; exertional symptoms; Pemberton positive	Awake FOI preferred
IV	Stridor at rest; tracheomalacia; retrosternal; tumour invasion	Awake FOI mandatory; tracheostomy kit open; cardiothoracic backup

Airway Management Strategies

1. Awake Fibreoptic Intubation (AFOI) — Gold Standard

Indications in thyroid: Stridor at rest, tracheal diameter <10 mm, retrosternal extension, previous neck surgery, any CICO risk

Technique

Phase	Action
Preparation	Glycopyrrolate 0.2 mg IM (30 min before — antisialogogue)
Sedation	Dexmedetomidine 1 mcg/kg loading over 10 min → 0.5 mcg/kg/hr OR Midazolam 1–2 mg + Fentanyl 25–50 mcg IV
Topicalisation: Nasal	Xylometazoline (vasoconstriction) + Lidocaine 2% spray
Oropharynx	Lidocaine 10% spray (total dose limit: 4 mg/kg)
Subglottis	Spray-as-you-go through fibrescope suction port + transtracheal injection 2% lidocaine 2–3 mL
Intubation	Advance loaded ETT over fibrescope; confirm tracheal rings + carina; advance ETT; confirm bilateral ventilation + ETCO2
Then induce GA	After confirmed intubation

ETT choice:

Reinforced (armoured/wire-spiral) ETT — resists surgical kinking
Reduced size if tracheal compression confirmed: 5.5–7.0 mm ID

2. Video Laryngoscopy (VL)

C-MAC, McGrath, GlideScope
Improves glottic view in distorted anatomy
Not a substitute for AFOI if complete awake assessment needed
Cannot navigate past extrinsic tracheal compression below larynx

3. Awake Tracheostomy (Under Local Anaesthesia)

Indicated when: stridor at rest, severe tracheomalacia, failed AFOI, tumour invading trachea
Surgeon performs surgical tracheostomy at level below obstruction under LA before GA induced

Intraoperative Considerations

RLN monitoring: NIM ETT (Medtronic) with surface EMG electrodes on cuff — alerts surgeon to nerve proximity; requires NMB reversal before nerve testing (sugammadex)
Tube position confirmed distal to point of maximum tracheal compression (CT correlation)
Haemostasis: Meticulous — haematoma in small thyroid bed can be rapidly fatal

Extubation Strategy — "As Dangerous as Intubation"

Step	Action
Voice check	Ask patient to count — confirms RLN intact before extubation
Cuff leak test	Deflate cuff → air leaks around ETT → no tracheal oedema/tracheomalacia. If NO leak → delay extubation
Tube exchanger technique	Remove ETT over Aintree/Cook exchanger → supplement O2 via exchanger → guide for re-intubation if stridor; remove after 30 min if stable
Post-extubation monitoring	30 min in OR + PACU × 4–6 h minimum
If stridor post-extubation	Nebulised adrenaline 0.5 mL/kg (1:1000); dexamethasone 0.15 mg/kg; CPAP/NIV; re-intubate if worsening

Source: Miller's Anesthesia 10e, Chapter 55; Barash 9e, Chapter 29; Morgan & Mikhail 7e, Chapter 37.

QUESTION 14B: UNILATERAL RECURRENT LARYNGEAL NERVE (RLN) INJURY — DIAGNOSIS AND PERIOPERATIVE MANAGEMENT

Anatomy

Feature	Right RLN	Left RLN
Origin	Loops around right subclavian artery	Loops around arch of aorta (ligamentum arteriosum)
Course	Shorter, more lateral; mediastinal in upper thorax	Longer; full mediastinal course
Entry into larynx	Cricothyroid joint (posterior)	Cricothyroid joint (posterior)
Motor supply	ALL intrinsic laryngeal muscles except cricothyroid	Same
Key muscle	PCA (posterior cricoarytenoid) = sole abductor	Same

Cricothyroid — supplied by external branch of Superior Laryngeal Nerve (SLN) — not RLN
Injury to RLN → PCA paralysed → unopposed adductors → cord in paramedian/adducted position

Causes

Category	Examples
Thyroid surgery	Most common iatrogenic cause (permanent 0.5–2%)
Oesophagectomy	Left RLN (long course)
Cardiac/thoracic surgery	CABG, aortic arch, lung resection
Carotid endarterectomy	Ipsilateral RLN
Mediastinal mass	Lymphoma, aortic aneurysm (left RLN)
Malignant invasion	Thyroid, lung, oesophageal, mediastinal
Idiopathic	Viral (HSV) neuritis
Intubation injury	Cuff pressure at cricothyroid joint

Clinical Features

Feature	Description
Dysphonia (hoarse, breathy voice)	Most consistent — glottal gap, incomplete adduction
Voice fatigue	Prolonged speaking worsens hoarseness
Ineffective cough	Cannot generate glottic closure for cough reflex
Aspiration	Especially thin liquids; may be silent
Stridor	Rare with unilateral (bilateral injury → stridor)
Respiratory distress	Absent with unilateral; bilateral = life-threatening

Diagnosis

Investigation	Findings	Purpose
Flexible nasolaryngoscopy (awake)	Gold standard — affected cord paramedian/adducted; contralateral compensation	Confirms paralysis and cord position
Laryngeal stroboscopy	Mucosal wave analysis	Differentiates neurological from mechanical fixation
Laryngeal EMG	TA + PCA muscles	Distinguishes neurapraxia (reversible) from axonotmesis/neurotmesis (permanent)
CT neck/chest/mediastinum	Identifies cause along full RLN course	Especially important for left RLN — aortic, mediastinal pathology
Video Fluoroscopic Swallow Study (VFSS)	Aspiration pattern	Guides SALT referral; dietary modifications
CXR / CT thorax	For left RLN — aortic, mediastinal	Malignancy or aneurysm

Perioperative Management

Preoperative

Baseline nasolaryngoscopy before ALL thyroid surgery — medicolegal + clinical
If pre-existing unilateral paralysis: Contralateral thyroid surgery risks bilateral paralysis → immediate post-op stridor/complete obstruction → tracheostomy plan prepared and consent taken
VFSS and SALT referral if aspiration demonstrated; thickened fluids preoperatively

Intraoperative

Measure	Detail
IONM (Intraoperative Neuromonitoring)	NIM ETT (Medtronic) — stainless steel electrodes in cuff; EMG from vocalis/thyroarytenoid during surgeon stimulation
Loss of signal (LOS)	Abrupt EMG amplitude drop >50% = RLN injury; surgeon alerted immediately
Benefit	Reduces permanent RLN injury from 0.5% to 0.1–0.2%
NMB requirement	Minimal/no NMB at time of nerve testing — use sugammadex for rapid reversal if needed

Immediate Post-Operative

Situation	Action
Voice check in OR	Ask patient to phonate before extubation
Cuff leak test	Mandatory (see Q14A)
Post-extubation stridor	Assess for bilateral injury; nebulised adrenaline 5 mL 1:1000; Heliox (70% He/30% O2); emergency reintubation + tracheostomy if bilateral injury

Long-Term Management

Treatment	Indication / Detail
Watchful waiting	Mild unilateral; hope for spontaneous recovery (neurapraxia → 3–6 months)
Voice therapy (SALT)	Compensatory techniques; voice exercises
Injection laryngoplasty (medialization)	Filler (fat, Radiesse) injected lateral to affected cord; temporary 3–12 months; improves phonation
Thyroplasty (Type I)	Permanent medialization; silastic/Gore-tex implant; performed under LA (awake voice testing)
Arytenoid adduction	Combined with thyroplasty for marked posterior glottic gap
Laryngeal reinnervation	Ansa cervicalis–RLN anastomosis; prevents atrophy; emerging technique

Source: Miller's Anesthesia 10e, Chapter 55; Barash 9e, Chapter 29; Morgan & Mikhail 7e, Chapter 37.

QUESTION 15A: PREMEDICATION IN CHILDREN

Definition and Goals

Premedication = administration of drugs prior to anaesthetic induction to achieve specific objectives in the paediatric patient.

Goal	Rationale
Anxiolysis	Separation anxiety peaks 6 months–6 years
Sedation	Facilitates smooth parental separation and IV placement
Analgesia	Preemptive pain management
Antisialogogue	Reduces secretions (especially with ketamine; inhalational induction)
Antiemesis	PONV prophylaxis (high-risk procedures)
Amnesia	Reduces unpleasant preoperative memories
Aspiration prophylaxis	H2 blockers / PPI in high-risk children

Note: Non-pharmacological measures should always be used first — parental presence, distraction, videos, EMLA cream.

Non-Pharmacological Premedication

Method	Notes
Parental presence at induction (PPIA)	Most effective age 2–10 years; less effective in very anxious parents
Distraction (tablet, videos, bubbles, music)	Reduces cortisol levels; effective across all ages
EMLA cream (2.5% lidocaine + 2.5% prilocaine)	Apply to IV site 60 min before; reduces cannulation pain; MetHb risk in infants <3 months
Preoperative theatre visit	Familiarise with mask and equipment
Child life specialist	Play therapy, preparation

Pharmacological Agents

1. MIDAZOLAM — Most Widely Used

Route	Dose	Onset	Duration	Notes
Oral	0.5 mg/kg (max 15–20 mg)	20–30 min	45–60 min	Mix in sweet juice; most practical
Intranasal	0.2–0.3 mg/kg	10 min	30 min	Rapid onset; stinging
IM	0.1–0.15 mg/kg	10–15 min	30–45 min	Painful; avoid if oral/IV possible
IV	0.03–0.05 mg/kg	2–3 min	20–30 min	Titrated
Rectal	0.3–0.5 mg/kg	20–30 min	45 min	Unpredictable absorption

Advantages: Anxiolysis, amnesia, anticonvulsant; flumazenil reversal available
Disadvantages: Paradoxical excitement 5–10% (especially 1–5 years); respiratory depression; may delay emergence from short cases

2. KETAMINE

Route	Dose	Onset	Notes
IM	4–6 mg/kg	3–5 min	Useful for combative, needle-phobic, autistic children; no IV required
IV	1–2 mg/kg	1–2 min	Induction dose
Oral	4–6 mg/kg	30 min	Mix with midazolam often
Intranasal	3–6 mg/kg	5–10 min	Increasingly used

Advantages: Provides sedation + analgesia + maintains airway reflexes; ideal for burn dressings, painful procedures, no IV access
Disadvantages: ↑ Salivation (add glycopyrrolate); emergence hallucinations (mitigated by midazolam); ↑ ICP/IOP (caution in neurotrauma, open eye)

3. DEXMEDETOMIDINE (Intranasal) — Growing Preference

Route	Dose	Onset	Notes
Intranasal	2–3 mcg/kg (200 mcg/mL concentrated solution)	25–45 min	Drop into nostril
IV	0.5 mcg/kg over 10 min	5–10 min	Slower titration

Advantages: Anxiolysis + sedation without respiratory depression; reduces emergence agitation; reduces opioid requirements; cardiac stable; superior prevention of emergence delirium vs midazolam
Disadvantages: Slow onset (plan 45 min before); bradycardia/hypotension; no antagonist; expensive

4. CLONIDINE (Oral — Alpha-2 Agonist)

Route	Dose	Onset
Oral	4 mcg/kg	45–90 min

Advantages: Anxiolysis + analgesia + reduces MAC; prevents emergence delirium; reduces PONV
Disadvantages: Long onset; prolonged postoperative sedation; bradycardia/hypotension

5. ANTISIALOGOGUE (Companion to Ketamine)

Drug	Dose	Route	Notes
Glycopyrrolate	0.01 mg/kg	IM/IV	Preferred — no BBB crossing; less tachycardia than atropine
Atropine	0.02 mg/kg (min 0.1 mg, max 0.5 mg)	IM/IV	Faster; crosses BBB; more tachycardia

6. Oral Analgesic Premedication

Drug	Dose	Notes
Paracetamol	15–20 mg/kg oral	60 min before; safe all ages
Ibuprofen	5–10 mg/kg oral	Avoid <6 months or renal disease
Celecoxib	100–200 mg oral	Adolescents; COX-2 selective

Special Situations Table

Situation	Preferred Agent	Reason
Uncooperative / autistic child	IM Ketamine 4–6 mg/kg	Reliable regardless of cooperation
Congenital heart disease	IN Dexmedetomidine 2 mcg/kg	No respiratory depression; haemodynamically stable
Emergence agitation risk (ENT/sevoflurane)	IN Dexmedetomidine OR IV ketamine 0.25 mg/kg at induction	Best evidence for agitation prevention
Infant <6 months	Minimal pharmacological premedication	EMLA + parental presence sufficient
Known paradoxical midazolam reaction	Avoid midazolam → dexmedetomidine or ketamine	Paradoxical disinhibition in 5–10%
Full stomach (emergency)	Omeprazole 1 mg/kg oral 2h before + RSI	Aspiration prophylaxis

Source: Barash 9e, Chapter 44; Morgan & Mikhail 7e, Chapter 44; Miller's Anesthesia 10e, Chapter 93.

QUESTION 15B: MASSIVE TRANSFUSION PROTOCOL (MTP) IN OBSTETRIC HAEMORRHAGE

Definition

Massive obstetric haemorrhage:

Blood loss >1500 mL, OR
Any blood loss causing haemodynamic instability, OR
Transfusion of ≥4 units PRBC in 4 hours, OR
Loss of >50% blood volume in 3 hours

MTP: Pre-established, coordinated, standardised protocol for rapid fixed-ratio blood product delivery to treat life-threatening haemorrhage and prevent the Lethal Triad (hypothermia + acidosis + coagulopathy).

(Barash 9e, Chapter 41; Miller's Anesthesia 10e, Chapter 61; Morgan & Mikhail 7e, Chapter 41)

Why Obstetric Haemorrhage Is Different

Feature	Significance
Leading cause of maternal mortality worldwide	~27% of maternal deaths
Fibrinogen is the first factor to fall	Normal pregnancy fibrinogen 4–6 g/L → falls rapidly in PPH
Hyperfibrinolysis	Hallmark of obstetric DIC; peaks at placental delivery
Rapid onset coagulopathy	Dilutional + consumptive + fibrinolytic combined
Fibrinogen <2 g/L	Predictive of massive haemorrhage progression

Activating the MTP

Trigger criteria (any one):

Blood loss >1500 mL
Continued active bleeding not responding to uterotonics
SBP <90 mmHg, HR >120 despite initial resuscitation
Suspected DIC (abnormal coagulation/TEG)

Activation: Senior obstetrician + cardiac anaesthesiologist notify blood bank → fixed-ratio packs dispatched immediately

Fixed-Ratio MTP: 1:1:1 (Damage Control Resuscitation)

Blood Product	Ratio	Purpose
Packed Red Blood Cells (PRBC)	1	Oxygen-carrying capacity; restore Hb
Fresh Frozen Plasma (FFP)	1	All clotting factors; target INR <1.5
Platelets	1 (per 4–6 PRBC)	Target >50 × 10⁹/L (>75 if CNS/active)
Cryoprecipitate	2 pools (10 units)	Fibrinogen + vWF + Factor XIII; target Fbg >2 g/L

Practical MTP Pack Schedule

Pack	Timing	Contents
Pack 1	0–30 min (immediate)	4 PRBC + 4 FFP
Pack 2	30–60 min	4 PRBC + 4 FFP + 1 apheresis platelet
Pack 3	60+ min	4 PRBC + 4 FFP + 1 apheresis platelet + 2 pools cryoprecipitate

Continue activating packs every 20–30 minutes until haemorrhage controlled.

Tranexamic Acid (TXA) — MANDATORY

WOMAN Trial (Lancet, 2017): TXA 1g IV within 3 hours of PPH onset reduced PPH-related death by 31% (RR 0.69, P=0.045). Greatest benefit when given within 3 hours.

Parameter	Detail
Dose	1 g IV over 10 min as soon as major PPH diagnosed
Second dose	1 g IV at 30 minutes if bleeding continues
Mechanism	Blocks lysine-binding sites on plasminogen → inhibits fibrinolysis → stabilises clot
Safety	No increased thrombosis in obstetric patients; safe in breastfeeding
Practical rule	Give TXA simultaneously with calling for blood — do not wait

Fibrinogen — Priority Target in Obstetric Haemorrhage

Source	Dose	Fibrinogen Rise	Note
Cryoprecipitate (2 pools = 10 units)	Standard	~1 g/L	Contains vWF, Factor VIII, Factor XIII
Fibrinogen concentrate (Haemocomplettan/RiaSTAP)	2–4 g IV	1 g/L per gram given	Factor-virus-inactivated; no thawing; faster delivery

ROTEM-guided approach: FIBTEM A5 <12 mm → give fibrinogen concentrate 2–4 g (more precise)
Target fibrinogen ≥2 g/L throughout active haemorrhage

Calcium Replacement

Massive transfusion → citrate in PRBC chelates ionised calcium → hypocalcaemia → cardiac depression + coagulopathy
Calcium chloride 10% — 10 mL (3.5 mmol) IV after every 4 units PRBC
OR Calcium gluconate 10% — 30 mL (slower release)
Target ionised Ca²⁺ >1.1 mmol/L (check ABG)

Uterotonics Table

Drug	Dose / Route	Notes
Oxytocin	5 units slow IV bolus + 40 units in 500 mL Hartmann's over 4h	First-line; SLOW bolus only (rapid → severe hypotension)
Ergometrine	0.2 mg IM/IV	Avoid in hypertension, Raynaud's, cardiac disease
Carboprost (PGF2α)	0.25 mg IM every 15 min (max 8 doses)	Avoid in asthma
Misoprostol	800–1000 mcg sublingual/rectal	WHO first-line where oxytocin unavailable

Vasopressors

Drug	Dose	Notes
Noradrenaline	0.1–0.3 mcg/kg/min IV	Preferred vasopressor; titrate to MAP ≥65 mmHg
Vasopressin	0.03 units/min IV	Adjunct to noradrenaline

The Lethal Triad — Prevention

Component	Prevention
Hypothermia	Warmed IV fluids (Level 1 warmer); forced-air warming; warm theatre ≥22°C
Acidosis	Rapid haemorrhage control; adequate perfusion; balanced crystalloids (avoid 0.9% NaCl)
Coagulopathy	Early FFP + platelets + cryoprecipitate/fibrinogen; TXA; avoid haemodilution

Monitoring During MTP

Parameter	Target
Haemoglobin	≥80 g/L during active haemorrhage
Platelets	≥50 × 10⁹/L (≥75 if CNS/active bleeding)
INR	≤1.5
Fibrinogen	≥2 g/L
Ionised Ca²⁺	≥1.1 mmol/L
Temperature	≥36°C
pH / Lactate	pH >7.2; lactate <4 mmol/L
TEG/ROTEM	Guides specific component therapy

Surgical Escalation Ladder (Haemorrhage Control)

Step	Intervention
1	Uterine compression + bimanual massage
2	Uterotonics (oxytocin → ergometrine → carboprost)
3	Uterine compression sutures (B-Lynch suture)
4	Uterine balloon tamponade (Bakri balloon)
5	Bilateral uterine artery ligation (O'Leary suture)
6	Bilateral internal iliac artery ligation
7	Uterine artery embolisation (if haemodynamically stable — interventional radiology)
8	Peripartum hysterectomy — definitive; save maternal life

MTP Timeline Checklist

Time	Key Actions
0 min	Activate MTP; call team; 2 large-bore IVs; O-negative blood; rapid infuser
0–5 min	TXA 1g IV; oxytocin; bimanual compression; blood cultures; coag + TEG
5–15 min	MTP Pack 1 (4 PRBC + 4 FFP); calcium chloride 10 mL; warm IV fluids; Foley catheter
15–30 min	Reassess TEG/ROTEM; fibrinogen <2 g/L → fibrinogen concentrate; MTP Pack 2
30–60 min	Surgical escalation; consider IR embolisation; review hysterectomy if uncontrolled
Ongoing	Serial ABG + coag + TEG every 30 min; reassess blood product ratio; warm theatre

Source: Barash 9e, Chapter 41; Miller's Anesthesia 10e, Chapters 61 & 77; Morgan & Mikhail 7e, Chapter 41; WOMAN Trial (Lancet 2017); OBS2 Trial (2021); RCOG PPH Guidelines 2023.

Questions 11–15 have been fully rewritten with the same detailed content as before, now restructured with clear section headings, organised tables, crisp bullets, and protocol algorithms throughout. Ready to continue with Questions 21–25 whenever you're ready!

This is a shared conversation. Sign in to Orris to start your own chat.